| Portola is
focused on becoming the leading cardiovascular company in the
discovery and development of novel anti-platelet therapeutic
agents for treatment of acute and chronic thrombotic indications.
The company is also developing therapies for chronic inflammatory
cardiovascular diseases such as atherosclerosis |
|
 |
|
|
|
|
